Civitas is a privately-held biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically proven ARCUS(R) dry powder pulmonary delivery platform. In addition to the lead program, CVT-301 for treating Parkinson's disease, other programs encompass respiratory disease, central nervous system disorders, and infectious disease. The company is headquartered in Chelsea, Mass. in a facility that includes both development and commercial scale GMP manufacturing capabilities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/11/13 | $38,000,000 | Series B |
Alkermes Bay City Capital Canaan Partners Fountain Healthcare Partners Longitude Capital RA Capital | undisclosed |
| 08/26/14 | $55,000,000 | Series C |
Adage Capital Management Alkermes Bay City Capital Canaan Partners Fountain Healthcare Partners Longitude Capital OrbiMed Advisors Partner Fund Management RA Capital Rock Springs Capital Sofinnova Ventures Wellington Management Company | undisclosed |
